ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury
Description
<jats:title>Abstract</jats:title><jats:p>Angiotensin-converting enzyme 2 (ACE2) is a receptor for cell entry of SARS-CoV-2, and recombinant soluble ACE2 protein inhibits SARS-CoV-2 infection as a decoy. ACE2 is a carboxypeptidase that degrades angiotensin II, thereby improving the pathologies of cardiovascular disease or acute lung injury. Here we show that B38-CAP, an ACE2-like enzyme, is protective against SARS-CoV-2-induced lung injury. Endogenous ACE2 expression is downregulated in the lungs of SARS-CoV-2-infected hamsters, leading to elevation of angiotensin II levels. Recombinant Spike also downregulates ACE2 expression and worsens the symptoms of acid-induced lung injury. B38-CAP does not neutralize cell entry of SARS-CoV-2. However, B38-CAP treatment improves the pathologies of Spike-augmented acid-induced lung injury. In SARS-CoV-2-infected hamsters or human ACE2 transgenic mice, B38-CAP significantly improves lung edema and pathologies of lung injury. These results provide the first in vivo evidence that increasing ACE2-like enzymatic activity is a potential therapeutic strategy to alleviate lung pathologies in COVID-19 patients.</jats:p>
Journal
-
- Nature Communications
-
Nature Communications 12 (1), 6791-, 2021-11-23
Springer Science and Business Media LLC
- Tweet
Details 詳細情報について
-
- CRID
- 1360576118787876480
-
- ISSN
- 20411723
-
- Data Source
-
- Crossref
- KAKEN